Anton_Medvedev / Shutterstock.com
In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver.
In the final article of a four-part series, Sophie Topham of Marks & Clerk discusses the supplementary protection certificate manufacturing waiver
Although not strictly speaking an experimental use exemption, there is one further means by which the production of medicinal products is exempted from infringement, namely, the Supplementary Protection Certificate (SPC) manufacturing waiver.
SPCs provide an extension to the period of exclusivity provided by a patent, of up to five years, for pharmaceutical products or plant protection products. They are intended to compensate the patent owner for the time required to obtain marketing authorisation for the product.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Marks & Clerk, SPC manufacturing, stockpiling, infringement, patents, experimental use, Brexit, life sciences